The invention is directed to compounds of Formulae (I, II, III) or (IV): wherein R, R1, R2, R3, A1 and A2 are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially VEGFR-2 (KDR), c-fms, c-met and tie-2 kinases. The invention is also directed toward methods of preparation of the compounds of Formulae (I, II, III) and (IV).
                            该发明涉及具有以下
化学式(I,II,III)或(IV)的化合物:其中R,R1,R2,R3,A1和A2如规范中所述,以及它们的溶剂化合物、
水合物、互变异构体或药用可接受的盐,这些化合物抑制
蛋白酪氨酸激酶,特别是V
EGFR-2(KDR),c-fms,c-met和tie-2激酶。该发明还涉及制备具有
化学式(I,II,III)和(IV)的化合物的方法。